Oxygen Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

The oxygen production and distribution business operates under a multi-tiered regulatory architecture spanning drug licensing for medical oxygen, pressure equipment safety for storage and handling, and environmental compliance for air separation operations. The regulatory pathway differs materially based on product mix (medical versus industrial) and scale of operations.

• Drug Manufacturing Licence under the Drugs and Cosmetics Act, 1940: Required from State Drug Controller for medical oxygen production. Application via SUGAM portal with Form 27/28. Mandatory compliance with Schedule M for quality control laboratories and IP 2018 standards for oxygen purity (99.5% minimum for medical grade). Inspections at 18-month intervals.
• PESO Approval under the Static and Mobile Pressure Vessel Rules, 2016: Cryogenic storage tanks exceeding 1,000 litres water capacity require PESO certification for design, fabrication, and installation. Certificate of Fitness renewal every 5 years. Pressure relief valve calibration every 12 months by PESO-approved agencies.
• Environmental Clearance under EIA Notification 2006: Air separation units with compression capacity exceeding 10,000 Nm3/hr require prior environmental clearance from State Environment Impact Assessment Authority. Ambient air quality monitoring mandatory during construction and operations. Nozzle emission limits for nitrogen oxide from compression systems.
• BIS Certification under IS 4379 and IS 15495: Seamless steel gas cylinders for medical oxygen must conform to IS 4379:2003 (DOT specification) or IS 15495:2004 (ISO standard). Hydraulic test interval every 5 years. Marking requirements for gas type, purity, and manufacturer identification.
• Factory Licence under the Factories Act, 1948: Applicable when workforce exceeds 20 on any day. Registration with Directorate of Industrial Safety and Health. Submission of safety officer appointment, medical examination records, and emergency response plan.
• MSME Udyam Registration: Mandatory for enterprises with investment in plant and machinery up to Rs. 50 crore. Enables access to CGTMSE credit guarantee (coverage up to 85% of loan amount), PMEGP subsidy for micro enterprises, and priority sector lending classification for bank financing.
• GST Registration and Composition Scheme: Business with turnover below Rs. 1.5 crore may opt for composition scheme with 1% GST rate on supply. Input tax credit availability for capital goods, making the regular scheme more advantageous for larger facilities above Rs. 10 crore annual turnover.
• IEC and Export Licence for medical oxygen: Export of medical oxygen requires Drug Controller General of India approval under the Drugs and Cosmetics Rules, 1945, Rule 100. IEC mandatory for export documentation. Countries with WHO prequalification requirement may need additional batch testing certifications.

KAMRIT Financial Services LLP manages the complete regulatory filing lifecycle for the oxygen plant project, from initial site clearance and environmental impact assessment through PESO design approval, drug licence application, and BIS certification coordination. Our team maintains active engagement with State Drug Controllers in Gujarat, Maharashtra, Tamil Nadu, and Karnataka, the states with highest concentration of industrial oxygen demand and established manufacturing ecosystems.

The oxygen market bifurcates into medical oxygen (approximately 42% of volume) and industrial oxygen (58%), with distinct growth profiles and competitive dynamics. Medical oxygen demand is driven by hospital bed expansion (targeting 3 beds per 1,000 population), home healthcare penetration, and diagnostic centre proliferation, growing at 11-14% annually. Industrial oxygen consumption is led by steel manufacturing (40% of industrial volume), followed by pharma synthesis, water treatment, chemical processing, and food freezing applications.

Within industrial oxygen, the steel sector sub-segment registers fastest growth at 14-16% CAGR driven by capacity additions under the PLI scheme for specialty steel and the National Steel Policy target of 300 million tonnes annual capacity by 2030. The pharmaceutical sub-segment grows at 9-11% as API manufacturing shifts domestic under the PLI scheme for bulk drugs, requiring high-purity oxygen for oxidation reactions. The water treatment sub-segment is emerging at 7-9% growth as municipal corporations across Tier 2 and Tier 3 cities implement oxygenation systems for sewage treatment plants under the Swachh Bharat Mission.

The cylinder distribution model remains dominant for medical oxygen, accounting for 68% of revenues, while bulk liquid oxygen (Lox) supply to industrial customers through tanker distribution is growing at 12% annually. Gas integration into customer operations (vendor-managed inventory, pipeline supply to industrial parks) represents the highest-margin segment but requires substantial scale. The listed manufacturer in adjacent category has pioneered vendor-managed inventory contracts with automotive OEMs in Chennai and Gurgaon clusters, setting operational benchmarks for the project.

Project-specific demand drivers

• PLI scheme allocations
• Import substitution policy
• Localisation under PM Gati Shakti
• China+1 supply chain redirection
• Export-led demand to MENA and Africa

Oxygen production technology options include Pressure Swing Adsorption (PSA), Vacuum Swing Adsorption (VSA), and Cryogenic Air Separation Units (ASU), each with distinct capital and operating cost profiles suited to different market positions. PSA plants dominate the sub-Rs. 15 crore capex segment, offering 50-500 Nm3/hr oxygen purity of 90-93%. Equipment suppliers include Atlas Copco (Sweden), Ingersoll Rand (USA), Parker Hannifin (USA), and Indian manufacturers like Texel Industries and BKM Industries.

Capital cost benchmarks Rs. 8-12 lakh per Nm3/hr capacity, with power consumption of 0.45-0.55 kWh per Nm3/hr of oxygen produced. Turnkey PSA plants are available from domestic integrators including GTS India and Hydrogen Energy Systems at 20-30% lower cost than European suppliers, though with 15-20% higher maintenance overhead. Cryogenic ASU plants, required for capacities above 5,000 Nm3/hr, involve capital outlay of Rs. 60-85 crore for a 200 tonne-per-day facility.

Major equipment suppliers include Linde Engineering (Germany), Air Liquide (France), and Chart Industries (USA) for cold box and heat exchanger packages. Indigenous ASU manufacturing capability is emerging through Linde India's Sriperumbudur facility and INOX Air Products' manufacturing base in Sanand. Cryogenic oxygen production achieves 99.5% purity at energy consumption of 0.35-0.42 kWh per Nm3/hr, materially lower than PSA but requiring higher fixed operating costs.

For the project's mid-range CapEx scenario of Rs. 25-45 crore, a VSA-based plant offers optimal balance between purity specifications and operating economics. VSA plants achieve 93-95% oxygen purity at 0.38-0.48 kWh per Nm3/hr, suited for industrial customers in steel and chemical sectors who require oxygen at purity above 90% but not medical-grade 99.5%. Energy costs constitute 55-65% of total operating expenditure in gas production, making power tariff negotiations critical.

Gujarat, Tamil Nadu, and Maharashtra offer industrial power tariffs of Rs. 5.5-7.0 per kWh, significantly lower than northern states.

The project's CapEx range of Rs. 6.5 crore to Rs. 112 crore warrants differentiated financing structures. For mid-scale PSA/VSA facilities (Rs. 10-30 crore), KAMRIT recommends a debt-equity ratio of 65:35 drawing from the following sources.

Term loans from SIDBI (up to Rs. 15 crore at 8.5-10.5% interest under the SIDBI Stand-Up India programme) and PSB consortiums including SBI and Bank of Baroda offer competitive rates for MSME-classified enterprises. CGTMSE guarantee coverage of up to 85% of the loan amount reduces collateral requirements, enabling promoter contribution as low as 20% of project cost. State MSME schemes in Gujarat (MGVCL Subsidy), Maharashtra (Maharashtra State Innovation Startup Policy), and Tamil Nadu (TANSIIC funding) provide capital subsidy of 10-15% of fixed capital investment, directly reducing equity requirement.

For large-scale ASU projects exceeding Rs. 50 crore, ICICI Bank and HDFC Bank's corporate banking arms offer project finance structures at leverage of 70:30 with 7-10 year tenor. IREDA financing applies for oxygen plants serving renewable energy manufacturing clusters, with interest rates starting at 6.5% for green manufacturing classifications. Axis Bank's equipment finance vertical provides machinery-specific financing for imported gas separation equipment with deferred LC payment structures.

Working capital requirements of Rs. 2.5-4.0 crore (approximately 45-60 days of operating expense) are recommended through revolving credit facilities from the consortium bank, secured against inventory of filled cylinders and receivables from established industrial customers. Export credit facilities from EXIM Bank support international sales contracts to MENA buyers with letters of credit confirmation structures.

PLI benefits under the Production Linked Incentive Scheme for Pharmaceuticals and Bulk Drugs (allocation Rs. 6,940 crore for FY2021-2025) may apply if the project supplies oxygen to domestic API manufacturing units, providing 5-8% incentive on incremental sales over the baseline year.

The three primary risks for this project are distinct from generic manufacturing risks and require structured mitigation. Demand concentration risk: Medical oxygen revenue may compress post-pandemic as hospital systems optimize inventory management and reduce safety stock holdings. The multi-national subsidiary with India operations has reported medical oxygen volumes declining 18-25% from FY2022 peaks in certain regions.

Mitigation requires diversification into industrial customer base within 24 months of operations, with no single customer exceeding 20% of revenue. Long-term supply agreements with steel manufacturers provide revenue floor at contracted volumes. Energy cost escalation risk: Power constitutes 55-65% of operating costs, and electricity tariff increases of Rs. 0.5-1.0 per kWh would compress EBITDA margins by 8-12 percentage points.

The project must negotiate power purchase agreements with 3-year fixed tariff clauses and explore solar rooftop installations (MNRE-compliant through PM-KUSUM scheme) to hedge 25-30% of energy consumption. Hybrid tariff structures with banking provisions for night-time production reduce peak demand charges. Regulatory and compliance risk: Drug licence renewal is subject to inspection findings, and any adverse observation can halt production pending corrective action.

Changes in BIS cylinder testing requirements or PESO pressure vessel regulations could impose capital expenditure for retrofitting. Mitigation involves engaging with regulatory consultants for pre-inspection compliance audits and maintaining documented quality management systems aligned with Schedule M requirements. The bankable DPR includes a compliance calendar with assigned responsibilities and budget allocation of Rs. 12-18 lakh annually for regulatory management.

Sensitivity analysis across scenarios of 10% volume decline, 15% power tariff increase, and 10% capacity underutilization indicates the project maintains debt service coverage ratio above 1.25 across all scenarios at the recommended debt-equity structure.